<DOC>
	<DOCNO>NCT02273817</DOCNO>
	<brief_summary>This study evaluate equivalence generic ciclesonide nasal spray market drug , Omnaris™ nasal spray , treatment seasonal allergic rhinitis , evaluate safety tolerability generic ciclesonide nasal spray compare Omnaris™ nasal spray .</brief_summary>
	<brief_title>A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray ( Apotex , Inc. ) To That Of Omnaris™ Nasal Spray ( Sepracor , Inc. ) In The Treatment Of Seasonal Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>If female childbearing potential , pregnant ( confirm negative urine pregnancy test ) lactating must use reliable birth control measure throughout study . At least 2year reliable medical history consistent SAR Positive skin test within 12 month screen least one seasonal allergen present geographical area Capable tolerate intranasal application IMP , willing able comply requirement protocol No clinically significant finding physical nasal examination , medical history . A reflective TNSS least 6 ( 12 ) 24 hour prior placebo leadin visit . Successfully complete placebo leadin period . Signs symptoms nasal polyp , deviate septum , condition , opinion Investigator , could result erroneous study data . Undergo nasal surgery nasal trauma within 3 month screen . Active respiratory condition respiratory tract infection require antibiotic treatment within 2 week screen Persistent allergic rhinitis ( PAR ) require expect require active PAR treatment study period . Evidence unstable clinically significant condition would place subject increase risk complication , interfere study participation , confound study objective . Presence history clinically significant condition opinion Investigator would compromise safety subject conduct study . Use corticosteroid , intranasal cromolyn , Leukotriene inhibitor , long short act antihistamine , intranasal systemic decongestant prior start singleblind , placebo leadin visit within time period specify protocol receive immunotherapy . Use investigational drug within 30 day screen study . Known suspect hypersensitivity corticosteroid . Inability avoid exposure chicken pox measles . Infection require oral antibiotic treatment 2 week prior screen . Previously identify placebo responder know non responder corticosteroid . History alcohol , drug , substance abuse 12 month prior Visit 1 ( screen ) . Positive hepatitis B C , human immunodeficiency virus ( HIV ) . Uncooperative non compliant . Female subject plan become pregnant conduct study . Current smoker ( former smoker 6 month smoke free ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>